Comparative arrhythmia patterns among patients on tyrosine kinase inhibitors. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing Wei, C., Fazal, M., Loh, A., Kapoor, R., Gomez, S. E., Shah, S., Rogers, A. J., Narayan, S. M., Wang, P. J., Witteles, R. M., Perino, A. C., Cheng, P., Rhee, J. W., Baykaner, T. 2023


Tyrosine kinase inhibitors (TKIs) are widely used in the treatment of hematologic malignancies. Limited studies have shown an association between treatment-limiting arrhythmias and TKI, particularly ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor. We sought to comprehensively assess the arrhythmia burden in patients receiving ibrutinib vs non-BTK TKI vs non-TKI therapies.We performed a retrospective analysis of consecutive patients who received long-term cardiac event monitors while on ibrutinib, non-BTK TKIs, or non-TKI therapy for a hematologic malignancy between 2014 and 2022.One hundred ninety-three patients with hematologic malignancies were included (ibrutinib?=?72, non-BTK TKI?=?46, non-TKI therapy?=?75). The average duration of TKI therapy was 32 months in the ibrutinib group vs 64 months in the non-BTK TKI group (p?=?0.003). The ibrutinib group had a higher prevalence of atrial fibrillation (n?=?32 [44%]) compared to the non-BTK TKI (n?=?7 [15%], p?=?0.001) and non-TKI (n?=?15 [20%], p?=?0.002) groups. Similarly, the prevalence of non-sustained ventricular tachycardia was higher in the ibrutinib group (n?=?31, 43%) than the non-BTK TKI (n?=?8 [17%], p?=?0.004) and non-TKI groups (n?=?20 [27%], p?=?0.04). TKI therapy was held in 25% (n?=?18) of patients on ibrutinib vs 4% (n?=?2) on non-BTK TKIs (p?=?0.005) secondary to arrhythmias.In this large retrospective analysis of patients with hematologic malignancies, patients receiving ibrutinib had a higher prevalence of atrial and ventricular arrhythmias compared to those receiving other TKI, with a higher rate of treatment interruption due to arrhythmias.

View details for DOI 10.1007/s10840-023-01575-z

View details for PubMedID 37256462